Targeting complement activation in COVID-19

Hrishikesh S. Kulkarni; John P. Atkinson

doi:10.1182/BLOOD.2020008925

Targeting complement activation in COVID-19

Hrishikesh S. Kulkarni, John P. Atkinson

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

In this issue of Blood, Yu et al have demonstrated that acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike proteins activate complement by engaging the alternative pathway (AP) and that blocking this process by inhibiting factor D or C5 could mitigate SARS-CoV-2–induced immunopathology.

Original language	English
Pages (from-to)	2000-2001
Number of pages	2
Journal	Blood
Volume	136
Issue number	18
DOIs	https://doi.org/10.1182/BLOOD.2020008925
State	Published - Oct 29 2020

Access to Document

10.1182/BLOOD.2020008925

Cite this

@article{f3a9b7a6690946d28d50770c480ef406,

title = "Targeting complement activation in COVID-19",

abstract = "In this issue of Blood, Yu et al have demonstrated that acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike proteins activate complement by engaging the alternative pathway (AP) and that blocking this process by inhibiting factor D or C5 could mitigate SARS-CoV-2–induced immunopathology.",

author = "Kulkarni, {Hrishikesh S.} and Atkinson, {John P.}",

year = "2020",

month = oct,

day = "29",

doi = "10.1182/BLOOD.2020008925",

language = "English",

volume = "136",

pages = "2000--2001",

journal = "Blood",

issn = "0006-4971",

number = "18",

}

TY - JOUR

T1 - Targeting complement activation in COVID-19

AU - Kulkarni, Hrishikesh S.

AU - Atkinson, John P.

PY - 2020/10/29

Y1 - 2020/10/29

N2 - In this issue of Blood, Yu et al have demonstrated that acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike proteins activate complement by engaging the alternative pathway (AP) and that blocking this process by inhibiting factor D or C5 could mitigate SARS-CoV-2–induced immunopathology.

AB - In this issue of Blood, Yu et al have demonstrated that acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike proteins activate complement by engaging the alternative pathway (AP) and that blocking this process by inhibiting factor D or C5 could mitigate SARS-CoV-2–induced immunopathology.

UR - http://www.scopus.com/inward/record.url?scp=85094934400&partnerID=8YFLogxK

U2 - 10.1182/BLOOD.2020008925

DO - 10.1182/BLOOD.2020008925

M3 - Article

C2 - 33119763

AN - SCOPUS:85094934400

SN - 0006-4971

VL - 136

SP - 2000

EP - 2001

JO - Blood

JF - Blood

IS - 18

ER -

Targeting complement activation in COVID-19

Abstract

Access to Document

Other files and links

Fingerprint

Cite this